Aspire Biopharma (ASBP) Competitors $0.39 0.00 (-1.18%) As of 08:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ASBP vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Aspire Biopharma stock or one of its competitors? The main competitors of Aspire Biopharma include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Aspire Biopharma vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and Aspire Biopharma (NASDAQ:ASBP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings. Does the media prefer ATNFW or ASBP? In the previous week, Aspire Biopharma had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for 180 Life Sciences. Aspire Biopharma's average media sentiment score of 0.91 beat 180 Life Sciences' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Aspire Biopharma Positive Which has higher earnings and valuation, ATNFW or ASBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AAspire BiopharmaN/AN/AN/AN/AN/A Is ATNFW or ASBP more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Aspire Biopharma N/A N/A N/A Does the MarketBeat Community believe in ATNFW or ASBP? 180 Life Sciences and Aspire Biopharma both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/AAspire BiopharmaOutperform VotesNo VotesUnderperform Votes1100.00% Do institutionals & insiders have more ownership in ATNFW or ASBP? 19.2% of Aspire Biopharma shares are held by institutional investors. 48.0% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAspire Biopharma beats 180 Life Sciences on 4 of the 4 factors compared between the two stocks. Get Aspire Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASBP vs. The Competition Export to ExcelMetricAspire BiopharmaPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$19.32M$6.66B$2.02B$8.57BDividend YieldN/A2.62%2.63%4.19%P/E RatioN/A8.5322.6619.93Price / SalesN/A381.6864.45154.99Price / CashN/A65.8551.7234.64Price / BookN/A6.492.124.63Net IncomeN/A$143.44M-$292.00M$247.95M7 Day PerformanceN/A3.52%1.03%1.77%1 Month PerformanceN/A4.00%8.08%8.69%1 Year PerformanceN/A-0.24%14.82%10.70% Aspire Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASBPAspire BiopharmaN/A$0.39-1.2%N/AN/A$19.09MN/A0.00N/AATNFW180 Life SciencesN/A$0.01+8.1%N/A+43.7%$0.00N/A0.007Positive NewsGap UpHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-92.6%$0.00N/A0.002Gap UpAIMDWAinosN/A$0.16+6.9%N/A+188.2%$0.00$106,207.000.0040Positive NewsGap UpALVOWAlvotechN/A$2.17+5.9%N/A-18.5%$0.00$585.60M0.004Positive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.01-18.0%N/AN/A$0.00N/A0.0015Gap UpBFRIWBiofronteraN/A$0.09+1.9%N/AN/A$0.00$38.00M0.0070Gap DownBTMDWbioteN/A$0.02-11.1%N/AN/A$0.00$199.38M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.09+0.8%N/A-80.2%$0.00N/A0.008Positive NewsCELUWCelularityN/A$0.04+0.3%N/A+158.5%$0.00$54.22M0.00220Positive NewsGap Up Related Companies and Tools Related Companies ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives AIMDW Alternatives ALVOW Alternatives ACABW Alternatives BFRIW Alternatives BTMDW Alternatives BCTXW Alternatives CELUW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASBP) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASBP Stock Free ASBP Stock Alerts